Timothyc Dec News Today

ROCKVILLE, Md., April 08, 2024 -- Supernus Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ...

ROCKVILLE, Md., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...

ROCKVILLE, Md., Feb. 28, 2024 -- Supernus Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ...

Fourth quarter 2023 net sales of Qelbree® increased 97% to $46.4 million compared to fourth quarter 2022; Full year 2023 net sales of Qelbree increased 129% to $140.2 million compared to full year...

ROCKVILLE, Md., Feb. 13, 2024 -- Supernus Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ...

Raises full year 2023 adjusted operating earnings guidance range to $95 million to $110 million from previous range of $75 million to $100 millionTotal revenues of $153.9 million in the third...

ROCKVILLE, Md., Nov. 07, 2023 -- Supernus Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ...

ROCKVILLE, Md., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...

ROCKVILLE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS)

Jay is sharing his story of receiving an ADHD diagnosis and eventually finding his treatment approach with Qelbree15.7 million U.S. children, teens and adults estimated to have been diagnosed with